tailieunhanh - INTEGRATING COMPLEMENTARY MEDICINE INTO VETERINARY PRACTICE

The veterinary profession has made major diagnostic and therapeutic advances in the treatment of infectious and degenerative diseases. The incidence of chronic disease and cancer, however, has increased at alarming rates and is diagnosed at younger ages, even in puppies and kittens. Perhaps it is this rising incidence of degenerative diseases that has spawned an insatiable search by professionals, scientists, and animal guardians for alternative therapies. Such therapies are gentle in their action, more effective in their abilities to prevent disease, and hold the promise of true healing—a goal that modern medicine to date has only been able to control but not cure | Integrating Complementary Medicine into Veterinary Practice Robert Goldstein AUTHORS Paula Jo Broadfoot Richard E. Palmquist Karen Johnston Jiu Jia Wen. Barbara Fougere with Margo Roman jift ểỊỵ Blackwell Publishing INTEGRATING COMPLEMENTARY MEDICINE INTO VETERINARY PRACTICE Integrating Complementary Medicine into Veterinary Practice Edited by Robert s. Goldstein 2008 John Wiley Sons Inc. ISBN 978-0-813-82020-0 INTEGRATING COMPLEMENTARY MEDICINE INTO VETERINARY PRACTICE Edited by ROBERT S. GOLDSTEIN VMD Paula Jo Broadfoot DVM Richard E. Palmquist DVM Karen Johnston DVM Barbara Fougere BVSc Jiu Jia Wen DVM with Margo Roman DVM @WI LEY- BLACKWELL A John Wiley Sons Inc. .

• Y học thường thức
• INTEGRATIVE THERAPY
• ORGAN SYSTEM
• Endocrine Diseases
• Neurological Disorders
• Cancer Treatment
• Cancer Type
• BMC Cancer
• Colorectal cancer
• MEK inhibitor
• Targeted therapy
• Cancer stem cell
• Gene expression signature
• Breast cancer
• Quality of life
• Supportive care
• Integrative therapies
• Type 2 diabetes
• Within class differences
• Patients with type 2 diabetes
• Cancer risk
• First line
• Wild type
• Metastatic colorectal cancer
• BRAF wild type mCRC
• Gastric cancer
• Clinicopathological features
• Malignant potential
• Pure differentiated type
• EGC specific survival rates
• Cancer patient pathways
• Lung cancer
• Prostate cancer
• Ovarian cancer
• Cancer survival
• Cancer prognosis
• Antidiabetic medication
• Lynch syndrome
• Lynch like syndrome
• Familial colorectal cancer type X
• Prospective surveillance study
• Cervical cancer
• Relative risk
• Cancer occurrence
• Sexually transmitted diseases
• Prostate cancer diagnosis
• Gonadotropin releasing hormone agonists
• Type 2 diabetes mellitus
• Cancer risks
• Liver cancer
• Pancreas cancer
• Colon cancer
• Neurofibromatosis type 1
• Autosomal dominant genetic disorder
• Malignant tumours
• Gastrointestinal stromal tumours
• Body mass index
• Retrospective cohort study
• Cancer incidence
• Meta analysis
• Randomization balanced measured
• Prostate cancer risk
• Antidiabetic medications
• Risk factors
• Cancer development
• Diabetes duration
• Human insulin
• Angiotensin receptor blocker
• Transient receptor potential vanilloid type
• PC3 cell line
• Alpha1D adrenergic receptor
• Molecular sub type
• Heterogeneous disease
• Disease progression
• Human papillomavirus
• Type distribution
• Invasive cervical cancer
• Pre cancerous
• Wild type KRAS
• 5 fluorouracil
• Biliary tract cancer
• Amino acid transporter
• Prognostic factor
• L type amino acid transporter 1
• Membrane type 1 matrix metalloproteinase
• Oral squamous cell carcinoma
• Emerging observations indicate
• Gastroesophageal junction cancer
• Lauren classification
• Signet ring cells
• Borrmann type III
• Differentially expressed genes
• Prognostic model
• Diabetes mellitus
• Female diabetes
• Cox regression
• Laryngeal cancer